logo
Share SHARE
FONT-SIZE Plus   Neg

Novartis Gets Approval From European Commission For Jakavi - Quick Facts

Incyte Corporation (INCY) announced its strategic collaborator, Novartis, received approval from the European Commission for Jakavi, or INC424, ruxolitinib, an oral JAK 1 and JAK 2 inhibitor discovered by Incyte, for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, or chronic idiopathic myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

Myelofibrosis is a life-threatening blood cancer associated with progressive, debilitating symptoms that can severely impact quality of life and shorten survival. Novartis said the European Commission's decision was based on positive findings from the COMFORT, or COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy, clinical trial program.

Incyte entered into a worldwide collaboration and license agreement with Novartis in 2009. Novartis received exclusive rights to the development and potential commercialization of ruxolitinib in all hematology-oncology indications outside of the United States. Incyte retained exclusive rights for the development and commercialization of ruxolitinib in the United States, and received approval from the U.S. Food and Drug Administration in November 2011 for ruxolitinib, marketed in the United States under the brand name Jakafi.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
PepsiCo has placed reservations for 100 Tesla Semi trucks, reports said. The order booking, which is said to be the largest public one to date, is likely to cost the snack and beverage giant around $2 million. Tesla's electric commercial trucks is expected to begin production in 2019. It requires $20,000 for reservation for a truck, as per reports. Nordson Corp. (NDSN) is due to release its Q4 financial results after the bell today, with analysts polled by Thomson Reuters estimating earnings of $1.33 per share on revenue of $545.15 million. Year-Ago Numbers: * Net income - $75.9 Mln * EPS - $1.31 * Sales - $509 Mln Q4 Guidance: Expects... As most of us are painfully aware, the days of the pension are mostly gone. The percentage of employers still offering a traditional defined benefit pension plan to newly hired employees fell from about 50% to 5% between 1998 and 2015, according to advisory firm Willis Towers Watson. Many companies...
comments powered by Disqus
Follow RTT